Overview

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .
Phase:
Phase 1
Details
Lead Sponsor:
Ayana Pharma Ltd.,
Collaborator:
Lambda Therapeutic Research Ltd.
Treatments:
Doxorubicin
Liposomal doxorubicin